Cantor Fitzgerald Issues Positive Outlook for MNPR Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Monopar Therapeutics in a research report issued to clients and investors on Thursday, September 25th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings per share of ($1.33) for the year, up from their previous estimate of ($1.35). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Monopar Therapeutics’ FY2026 earnings at ($2.79) EPS.

MNPR has been the subject of several other reports. HC Wainwright set a $105.00 price objective on Monopar Therapeutics and gave the stock a “buy” rating in a research note on Monday. Raymond James Financial assumed coverage on Monopar Therapeutics in a research note on Tuesday, September 2nd. They issued a “strong-buy” rating and a $80.00 price objective for the company. BTIG Research raised their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Lake Street Capital initiated coverage on Monopar Therapeutics in a research report on Tuesday, September 23rd. They set a “buy” rating and a $106.00 price target for the company. Finally, Oppenheimer initiated coverage on Monopar Therapeutics in a research report on Wednesday, September 3rd. They set an “outperform” rating and a $77.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Monopar Therapeutics has a consensus rating of “Buy” and a consensus price target of $86.22.

Monopar Therapeutics Stock Up 7.6%

Shares of NASDAQ:MNPR opened at $81.67 on Monday. Monopar Therapeutics has a 52-week low of $4.50 and a 52-week high of $81.89. The stock has a market cap of $503.90 million, a price-to-earnings ratio of -24.53 and a beta of 1.20. The business has a 50-day moving average price of $45.78 and a 200-day moving average price of $40.11.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.12.

Insiders Place Their Bets

In other Monopar Therapeutics news, CEO Chandler Robinson sold 16,800 shares of the firm’s stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the sale, the chief executive officer directly owned 73,472 shares of the company’s stock, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Tactic Pharma Llc sold 550,229 shares of the firm’s stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the sale, the insider directly owned 272,026 shares in the company, valued at approximately $17,303,573.86. The trade was a 66.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 592,733 shares of company stock valued at $36,700,227 in the last three months. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Monopar Therapeutics

Several institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Monopar Therapeutics in the second quarter valued at approximately $80,000. Affinity Asset Advisors LLC grew its holdings in Monopar Therapeutics by 8.9% in the second quarter. Affinity Asset Advisors LLC now owns 67,500 shares of the company’s stock valued at $2,415,000 after purchasing an additional 5,500 shares during the period. New York State Common Retirement Fund acquired a new stake in Monopar Therapeutics in the second quarter valued at approximately $104,000. Rhumbline Advisers acquired a new stake in Monopar Therapeutics in the second quarter valued at approximately $209,000. Finally, JPMorgan Chase & Co. grew its holdings in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the period. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.